Free Newsletter
Corporate green goals driving PAT adoption
GlaxoSmithKline plant managers are jumping on the process analytical technology train. But process control is not the sole driver. GSK, like other drugmakers, is seeing PAT provide a boost for its sustainability efforts.
The trend is currently most apparent in its pilot plants, according to PharmaManufacturing.com. Managers trying to reduce cycle times and realize energy and cost savings are considering and adopting the technology.
In a recent survey conducted by the online magazine, ten percent of respondents say that sustainability has become a key driver of their PAT efforts. About half of the 50 respondents say they see PAT as a means toward sustainability and green practices.
PAT has "moved up in status, and moved upstream in the development cycle," according to the article. "Manufacturers are beginning to equate PAT with reducing the environmental impact of processes."
- here's the article
Related Articles:
Millipore boasts progress on green initiatives
Plant design emphasizes green
Pharma finds means to go green
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

SHARE
WITH: